Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSC in steroid-refractory GVHD
NCT04926194Phase 2Completed
- Sponsor
- University Health Network
- Start
- Mar 2021
- Primary completion
- Jun 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decidua stroma cells in graft-versus-host disease (GVHD), sponsored by University Health Network. Primary endpoints: Eastern Cooperative Oncology Group Performance Status at 6 weeks, Karnofsky Performance Status at 6 weeks and 6 more. Started Mar 2021; status: completed.
02
Drugs
decidua stroma cells
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04926194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04926194.